Skip to main content

Tivozanib Side Effects

Medically reviewed by Last updated on Jul 23, 2023.

Applies to tivozanib: oral capsule.

Serious side effects of Tivozanib

Along with its needed effects, tivozanib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking tivozanib:

More common

Other side effects of Tivozanib

Some side effects of tivozanib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to tivozanib: oral capsule.


Very common (10% or more): Activated partial thromboplastin time prolonged (26%), lymphocytes decreased (25%), hemoglobin increased (19%), platelets decreased (19%), bleeding (e.g., hematuria, epistaxis, hemoptysis, hematoma, rectal hemorrhage, vaginal hemorrhage, contusion, GI hemorrhage, hematochezia, intraocular hematoma, melena, metrorrhagia, pulmonary hemorrhage, subdural hematoma, gingival bleeding, hematemesis, hemorrhage intracranial, hemorrhoidal hemorrhage, splinter hemorrhages (17%), hemoglobin decreased (16%)[Ref]


Very common (10% or more): Back pain (19%)[Ref]


Very common (10% or more): Glucose increased (50%), phosphate decreased (38%), anorexia (39%), sodium decreased (36%), potassium increased (26%), magnesium decreased (26%), weight loss (17%), calcium increased (15%)[Ref]


Very common (10% or more): ALT increased (30%), alkaline phosphatase increased (30%), AST increased (30%), bilirubin increased (11%)[Ref]


Very common (10% or more): Dysphonia (27%), cough (22%), dyspnea (15%)[Ref]


Very common (10% or more): Fatigue/asthenia (67%)[Ref]


Serious adverse reactions occurred in 45% of patients who received this drug. Serious adverse reactions in greater than 2% of patients included bleeding (3.5%), venous thromboembolism (3.5%), arterial thromboembolism (2.9%), acute kidney injury (2.3%), and hepatobiliary disorders (2.3%). Fatal adverse reactions occurred in 8% of patients, including pneumonia (1.7%), hepatobiliary disorders (1.2%), respiratory failure (1.2%), myocardial infarction (0.6%), cerebrovascular accident (0.6%), and subdural hematoma (0.6%)[Ref]


Very common (10% or more): Creatinine increased (50%)[Ref]


Very common (10% or more): Hypertension/blood pressure increased/hypertensive crisis (44%)[Ref]


Very common (10% or more): Rash (e.g., dermatitis, dermatitis acneiform, dermatitis contact, drug eruption, eczema, eczema nummular, erythema, erythema multiforme, photosensitivity reaction, pruritus, psoriasis, rash erythematous, rash generalized, rash macular, rash maculopapular, rash morbilliform, rash pruritic, seborrheic dermatitis, skin exfoliation, skin irritation, skin lesion, swelling face, toxic skin eruption, urticaria) (18%), Palmar-plantar erythrodysesthesia syndrome[Ref]


Very common (10% or more): Hypothyroidism (including blood thyroid stimulating hormone increased, triiodothyronine decreased, triiodothyronine free decreased (44%)[Ref]


Very common (10% or more): Diarrhea (43%), lipase increased (32%), nausea (30%), amylase increased (23%), stomatitis (21%), vomiting (18%)[Ref]


1. Product Information. Fotivda (tivozanib). Aveo Pharmaceuticals, Inc. 2021.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.